▁Bre 8.0234375
ast 1.9580078125
▁cancer 1.6357421875
▁is 1.189453125
▁a 1.736328125
▁topic 5.7421875
▁that 0.7373046875
▁has 2.36328125
▁been 0.9892578125
▁widely 3.2265625
▁discussed 1.130859375
▁in 0.9892578125
▁recent 1.95703125
▁years 0.2169189453125
▁due 3.259765625
▁to 0.0110321044921875
▁its 1.796875
▁increasing 2.126953125
▁pre 0.794921875
val 0.0023441314697265625
ence 0.0005259513854980469
▁in 1.916015625
▁society 2.51953125
. 0.275390625
▁Many 4.32421875
▁factors 2.134765625
▁contribute 1.708984375
▁to 0.005832672119140625
▁the 0.55908203125
▁development 0.7353515625
▁of 0.05902099609375
▁breast 0.3740234375
▁cancer 0.0028362274169921875
, 0.10833740234375
▁including 0.459228515625
▁her 4.15625
ed 0.32958984375
ity 0.00028586387634277344
, 0.1763916015625
▁dise 11.5390625
ases 0.0141754150390625
▁of 2.59765625
▁the 0.11126708984375
▁m 3.796875
amm 0.01203155517578125
ary 0.0019683837890625
▁g 0.022918701171875
lands 0.41259765625
, 0.1363525390625
▁and 1.1259765625
▁h 2.4453125
orm 0.00102996826171875
onal 0.278076171875
▁factors 1.876953125
. 0.1463623046875
<0x0A> 1.38671875
H 3.35546875
ered 1.4208984375
ity 0.0025615692138671875
▁is 0.73828125
▁a 1.2763671875
▁critical 4.515625
▁factor 0.22900390625
▁in 0.31201171875
▁the 0.456787109375
▁development 0.1431884765625
▁of 0.01071929931640625
▁breast 0.09478759765625
▁cancer 0.003864288330078125
. 0.765625
▁If 2.55859375
▁a 0.68212890625
▁person 1.9599609375
▁has 0.83056640625
▁a 0.125
▁family 0.218994140625
▁history 0.1365966796875
▁of 0.00884246826171875
▁breast 0.271484375
▁cancer 0.01100921630859375
, 0.10015869140625
▁their 2.125
▁ch 2.44921875
ances 9.500980377197266e-05
▁of 0.00437164306640625
▁developing 0.053070068359375
▁the 0.359375
▁disease 0.0294036865234375
▁increase 1.3271484375
▁significantly 0.84765625
. 0.049835205078125
▁This 2.1953125
▁is 0.24658203125
▁because 0.431396484375
▁certain 1.634765625
▁gen 0.08837890625
es 0.70361328125
, 2.740234375
▁such 0.10699462890625
▁as 5.5909156799316406e-05
▁BR 0.365966796875
CA 0.0015726089477539062
1 0.0479736328125
▁and 0.035888671875
▁BR 0.00948333740234375
CA 0.0006361007690429688
2 0.002780914306640625
, 0.0107574462890625
▁are 0.72021484375
▁responsible 2.32421875
▁for 0.0002906322479248047
▁suppress 6.1328125
ing 0.00020313262939453125
▁tum 0.81396484375
or 0.27734375
▁growth 0.39794921875
. 0.67431640625
▁When 2.791015625
▁these 0.1285400390625
▁gen 0.003704071044921875
es 0.0005421638488769531
▁are 0.09527587890625
▁mut 0.470947265625
ated 0.0009632110595703125
, 0.3232421875
▁they 0.74169921875
▁are 3.0234375
▁no 1.947265625
▁longer 3.2901763916015625e-05
▁able 0.1441650390625
▁to 0.001468658447265625
▁do 2.541015625
▁their 0.11474609375
▁job 0.0160369873046875
▁effectively 3.041015625
, 0.275390625
▁leading 0.77587890625
▁to 0.0004303455352783203
▁an 0.74658203125
▁increased 0.2208251953125
▁risk 0.009185791015625
▁of 0.02227783203125
▁breast 1.0029296875
▁cancer 0.0026035308837890625
. 0.05731201171875
<0x0A> 0.116943359375
D 1.0810546875
ise 0.002231597900390625
ases 0.0081329345703125
▁of 0.0144500732421875
▁the 0.0016918182373046875
▁m 0.12261962890625
amm 0.00013971328735351562
ary 0.00040650367736816406
▁g 0.0006933212280273438
lands 0.0311737060546875
▁also 3.287109375
▁play 0.5478515625
▁a 0.0267486572265625
▁role 0.1424560546875
▁in 0.0037097930908203125
▁the 0.0859375
▁development 0.003749847412109375
▁of 0.0003771781921386719
▁breast 0.00449371337890625
▁cancer 0.00014925003051757812
. 0.004566192626953125
▁Cond 3.037109375
itions 3.0517578125e-05
▁such 0.0251617431640625
▁as 4.875659942626953e-05
▁at 4.90625
yp 0.1500244140625
ical 0.017730712890625
▁hyper 0.1573486328125
pl 0.0001538991928100586
asia 0.004093170166015625
▁and 0.505859375
▁lo 0.88818359375
b 0.0017957687377929688
ular 0.0019102096557617188
▁car 0.0284271240234375
cin 4.315376281738281e-05
oma 0.00064849853515625
▁in 0.06805419921875
▁situ 0.0018520355224609375
▁are 2.890625
▁known 1.97265625
▁to 0.098876953125
▁increase 0.040374755859375
▁the 0.1712646484375
▁risk 0.0309295654296875
▁of 0.0010805130004882812
▁developing 0.9638671875
▁breast 0.27197265625
▁cancer 0.0003082752227783203
. 0.1834716796875
▁These 0.6474609375
▁dise 1.3740234375
ases 7.390975952148438e-05
▁cause 1.9716796875
▁ab 0.7470703125
normal 0.0002359151840209961
▁growth 1.2275390625
▁of 0.11767578125
▁cells 0.59619140625
▁within 2.984375
▁the 0.00024771690368652344
▁breast 2.779296875
▁t 1.310546875
issue 0.00232696533203125
, 0.0791015625
▁which 0.2215576171875
▁can 0.06378173828125
▁eventually 0.4306640625
▁lead 0.2098388671875
▁to 6.4373016357421875e-06
▁the 0.322021484375
▁formation 1.1962890625
▁of 6.794929504394531e-05
▁tum 0.87548828125
ors 0.003879547119140625
. 0.01953125
<0x0A> 0.0224609375
H 0.276611328125
orm 0.0002295970916748047
onal 0.038116455078125
▁factors 0.00327301025390625
▁are 0.97119140625
▁another 1.54296875
▁critical 3.083984375
▁factor 0.34375
▁in 0.034881591796875
▁the 0.0087738037109375
▁development 0.0005464553833007812
▁of 0.0003323554992675781
▁breast 0.0001531839370727539
▁cancer 7.128715515136719e-05
. 0.002483367919921875
▁Est 0.6416015625
ro 0.0107574462890625
gen 3.0279159545898438e-05
, 2.15234375
▁a 2.89453125
▁h 1.009765625
orm 1.1920928955078125e-07
one 0.0003561973571777344
▁produced 1.130859375
▁in 1.9443359375
▁the 0.08660888671875
▁o 0.4658203125
var 1.621246337890625e-05
ies 0.0004482269287109375
, 0.0892333984375
▁has 2.75
▁been 0.039306640625
▁linked 1.1435546875
▁to 0.0027027130126953125
▁the 0.380859375
▁growth 1.296875
▁of 0.1722412109375
▁breast 0.1807861328125
▁cancer 0.11669921875
▁cells 0.15283203125
. 0.01136016845703125
▁Women 1.7763671875
▁who 0.315673828125
▁have 0.424560546875
▁higher 1.1484375
▁levels 0.0133056640625
▁of 2.8967857360839844e-05
▁est 0.0143585205078125
ro 0.0008687973022460938
gen 8.344650268554688e-06
▁in 0.09564208984375
▁their 0.0007872581481933594
▁bodies 0.08984375
, 3.58203125
▁either 1.2939453125
▁naturally 2.736328125
▁or 0.00812530517578125
▁through 1.15625
▁h 1.416015625
orm 1.430511474609375e-06
one 0.060272216796875
▁replacement 0.0740966796875
▁ther 0.00013840198516845703
apy 0.0005192756652832031
, 0.038726806640625
▁are 0.268798828125
▁at 0.1998291015625
▁a 0.37109375
▁higher 0.2274169921875
▁risk 6.794929504394531e-06
▁of 0.0216522216796875
▁developing 0.0012197494506835938
▁breast 0.11907958984375
▁cancer 7.224082946777344e-05
. 0.0089111328125
<0x0A> 0.19140625
Det 8.109375
ect 0.1876220703125
ing 0.0053253173828125
▁early 2.794921875
▁met 11.078125
ast 0.09039306640625
asis 0.861328125
▁is 2.02734375
▁cru 1.111328125
cial 0.0002357959747314453
▁in 0.423828125
▁the 0.49609375
▁treatment 0.371337890625
▁of 0.041046142578125
▁breast 0.0269012451171875
▁cancer 0.0003402233123779297
. 0.134765625
▁Met 1.599609375
ast 0.0005040168762207031
asis 0.0303192138671875
▁occurs 1.435546875
▁when 0.0002428293228149414
▁cancer 0.10052490234375
▁cells 0.06475830078125
▁spread 0.0654296875
▁to 0.56298828125
▁other 0.006908416748046875
▁parts 0.0771484375
▁of 4.267692565917969e-05
▁the 3.910064697265625e-05
▁body 8.344650268554688e-06
, 0.05523681640625
▁which 3.97265625
▁can 0.09014892578125
▁make 0.76318359375
▁the 0.884765625
▁disease 0.2451171875
▁much 3.544921875
▁more 0.1474609375
▁difficult 0.058074951171875
▁to 0.0016937255859375
▁treat 0.01239013671875
. 0.03350830078125
▁Reg 4.79296875
ular 0.00037741661071777344
▁screen 1.328125
ings 0.8525390625
, 0.308349609375
▁such 0.050018310546875
▁as 0.00012969970703125
▁m 0.0264129638671875
amm 3.933906555175781e-06
og 0.031646728515625
rams 1.7523765563964844e-05
▁and 0.494140625
▁clin 2.55859375
ical 0.0001310110092163086
▁breast 0.17626953125
▁ex 0.207763671875
ams 5.364418029785156e-06
, 0.00289154052734375
▁can 0.289794921875
▁help 0.11083984375
▁detect 0.27587890625
▁early 0.529296875
▁signs 1.041015625
▁of 0.00015544891357421875
▁met 0.3955078125
ast 3.0875205993652344e-05
asis 0.00626373291015625
. 1.3701171875
▁These 4.0078125
▁tests 1.2216796875
▁allow 4.1796875
▁do 0.3408203125
ctors 7.271766662597656e-06
▁to 0.0006246566772460938
▁identify 0.442138671875
▁the 4.08203125
▁presence 0.1767578125
▁of 0.001636505126953125
▁any 3.03125
▁ab 0.371826171875
normal 3.0875205993652344e-05
▁growth 2.42578125
s 0.031646728515625
▁or 0.56689453125
▁l 0.89794921875
umps 0.0031108856201171875
▁in 0.186279296875
▁the 0.0009326934814453125
▁breast 0.1978759765625
▁t 0.58154296875
issue 0.0011539459228515625
. 1.0654296875
<0x0A> 0.185546875
Det 6.3515625
erm 3.8359375
ining 0.024139404296875
▁the 0.1817626953125
▁ag 4.87890625
gress 0.01030731201171875
iveness 0.00864410400390625
▁of 0.015625
▁the 1.3935546875
▁cancer 0.6337890625
▁type 8.4453125
▁is 0.169189453125
▁essential 2.39453125
▁in 0.1839599609375
▁developing 1.8828125
▁a 1.251953125
▁treatment 0.345703125
▁plan 0.004344940185546875
. 0.2357177734375
▁Do 3.830078125
ctors 0.0036220550537109375
▁use 0.9111328125
▁various 1.498046875
▁methods 1.9658203125
▁to 0.4296875
▁determine 0.328369140625
▁the 0.034942626953125
▁stage 4.04296875
▁and 1.228515625
▁grade 1.01953125
▁of 0.00079345703125
▁breast 1.5478515625
▁cancer 0.0008020401000976562
, 0.5927734375
▁including 0.353515625
▁imag 2.060546875
ing 5.8531761169433594e-05
▁tests 0.1064453125
, 0.5341796875
▁bi 0.11798095703125
ops 0.00024318695068359375
ies 0.035797119140625
, 0.0027561187744140625
▁and 0.0037746429443359375
▁gen 2.48828125
etic 0.00024700164794921875
▁testing 0.340576171875
. 0.0018548965454101562
▁Im 3.859375
aging 0.00109100341796875
▁tests 0.0013475418090820312
, 0.426025390625
▁such 0.0029888153076171875
▁as 9.238719940185547e-05
▁M 3.58203125
RI 0.0007429122924804688
▁and 0.27490234375
▁CT 0.7529296875
▁sc 0.018341064453125
ans 5.745887756347656e-05
, 0.0007176399230957031
▁help 2.53125
▁do 0.37255859375
ctors 9.5367431640625e-06
▁assess 4.2890625
▁the 0.003208160400390625
▁size 0.278564453125
▁and 0.045379638671875
▁location 0.42333984375
▁of 1.5854835510253906e-05
▁tum 3.265625
ors 0.0015115737915039062
. 0.72998046875
▁Bi 0.0780029296875
ops 5.841255187988281e-06
ies 0.0025577545166015625
▁involve 1.22265625
▁extract 5.13671875
ing 1.5735626220703125e-05
▁a 0.1773681640625
▁small 0.5537109375
▁sample 0.2303466796875
▁of 0.000629425048828125
▁t 0.2352294921875
issue 0.0003209114074707031
▁for 2.154296875
▁further 2.013671875
▁exam 1.53125
ination 2.2530555725097656e-05
▁under 1.2626953125
▁a 0.00348663330078125
▁mic 0.0003352165222167969
ros 3.4570693969726562e-06
cope 1.1920928955078125e-06
, 1.9384765625
▁while 0.38037109375
▁gen 0.0017786026000976562
etic 0.00021648406982421875
▁testing 0.06903076171875
▁can 0.94091796875
▁identify 1.8623046875
▁specific 0.5361328125
▁gen 0.798828125
es 1.13671875
▁or 3.984375
▁mut 0.11309814453125
ations 0.00017511844635009766
▁that 0.1588134765625
▁may 0.15771484375
▁affect 3.484375
▁the 0.36376953125
▁ag 2.67578125
gress 0.002910614013671875
iveness 0.0012006759643554688
▁of 0.0178070068359375
▁the 0.023468017578125
▁cancer 0.1036376953125
. 0.06500244140625
<0x0A> 0.0350341796875
In 2.73828125
▁conclusion 1.5751953125
, 0.0003209114074707031
▁understanding 2.720703125
▁the 0.1435546875
▁critical 5.484375
▁factors 0.1258544921875
▁contrib 3.041015625
uting 4.935264587402344e-05
▁to 0.0003895759582519531
▁the 0.214111328125
▁development 0.01654052734375
▁of 0.019439697265625
▁breast 0.023529052734375
▁cancer 0.0004742145538330078
, 1.9072265625
▁including 1.138671875
▁her 0.0305328369140625
ed 0.004154205322265625
ity 2.384185791015625e-06
, 0.0013952255249023438
▁dise 0.1566162109375
ases 0.00011038780212402344
▁of 0.0022907257080078125
▁the 0.0016021728515625
▁m 0.0010213851928710938
amm 4.863739013671875e-05
ary 6.377696990966797e-05
▁g 0.0007047653198242188
lands 0.00229644775390625
, 0.00399017333984375
▁and 0.0293426513671875
▁h 0.0006165504455566406
orm 1.0728836059570312e-06
onal 0.003696441650390625
▁factors 0.0011110305786132812
, 0.031646728515625
▁is 0.15625
▁vital 3.853515625
▁for 1.4677734375
▁early 1.0107421875
▁detection 0.043304443359375
▁and 0.04461669921875
▁effective 0.86279296875
▁treatment 0.004116058349609375
. 0.076171875
▁Det 2.669921875
ect 0.0161590576171875
ing 0.00020837783813476562
▁early 0.061920166015625
▁met 0.033050537109375
ast 5.078315734863281e-05
asis 0.0010938644409179688
▁and 0.48486328125
▁determ 0.055511474609375
ining 9.179115295410156e-05
▁the 0.008209228515625
▁ag 0.0122528076171875
gress 0.0001342296600341797
iveness 0.0014886856079101562
▁of 0.0011749267578125
▁the 0.0714111328125
▁cancer 0.0070953369140625
▁type 0.034210205078125
▁are 0.125732421875
▁essential 1.2060546875
▁steps 1.111328125
▁in 0.01513671875
▁ens 3.578125
uring 2.300739288330078e-05
▁successful 2.55078125
▁out 1.4697265625
comes 6.794929504394531e-06
▁for 0.323486328125
▁patients 0.463134765625
▁with 0.58642578125
▁breast 0.01113128662109375
▁cancer 8.463859558105469e-05
. 0.00688934326171875
▁A 6.609375
war 1.1298828125
eness 1.0013580322265625e-05
▁and 0.472900390625
▁early 2.0703125
▁diagn 3.482421875
osis 0.0007781982421875
▁are 0.63623046875
▁key 1.4970703125
▁in 1.1484375
▁the 1.84765625
▁fight 0.06182861328125
▁against 0.0003581047058105469
▁this 0.86865234375
▁disease 0.630859375
. 0.46044921875
